|Hospital:||Sir Charles Gairdner Hospital|
|Patients: This Phase II study involved 53 patients with malignant pleural mesothelioma; 45 men and 8 women. The median age was 63 years.|
Treatment: The treatment consisted of two chemotherapy drugs; cisplatin (platinol) and gemcitabine (gemzar).
Toxicity: Grade 3-4 toxicities included hematologic, diarrhea, infection, neurotoxicity, vomiting, and nausea.
Results: Median survival was 11.2 months.
Support: The study was supported in part by Eli Lilly. This company markets gemzar.
Correspondence: M.J. Byrne, MD